Q2 2025 Earnings Call Transcript August 11, 2025 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported ...

Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with offices in Nashville, today ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of ...

PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to inclu ...

FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 di ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Cedars-Sinai physician-scientists joined peers from around the world at the Alzheimer's Association International Conference ...